Caution! The site can't guarantee, that text has age permission. The site is not recommended, if you are less than 18 years old.
The site shows example sentences for English words. How the word or phrase could be used in a sentence?
" ... AstraZeneca’s speed bump demonstrates the uncertain nature of vaccine development. On Saturday, AstraZeneca and Oxford University announced they were given permission by the British Medicines and Healthcare Products Regulatory Agency to restart the Phase 3 clinical trial of their investigational Covid-19 vaccine in the U.K. The trial is still on hold in the U.S. and other countries. ... "
" ... Nektar Therapeutics is our fourth Top Short of the day. Nektar Therapeutics is a biotech company that discovers and develops innovative medicines for high unmet medical needs, such as investigational drugs for cancer, auto-immune diseases, and chronic pain. Our AI systems rated the company B in Technicals, C in Growth, F in Low Volatility Momentum, and F in Quality Value. The stock closed up 3.52% to $20.6 on volume of 1,991,509 vs its 10-day price average of $19.02 and its 22-day price average of $18.42, and is up 16.65% for the year. Revenue grew by 42.49% in the last fiscal year, Operating Income grew by -13.91% in the last fiscal year, and EPS grew by -1.8% in the last fiscal year. Revenue was $114.62M in the last fiscal year compared to $307.71M three years ago, Operating Income was $(440.04)M in the last fiscal year compared to $(43.66)M three years ago, EPS was $(2.52) in the last fiscal year compared to $(0.62) three years ago, and ROE was (28.22%) in the last year compared to (109.91%) three years ago. ... "
" ... Nektar Therapeutics is our fourth Top Short of the day. Nektar Therapeutics is a biotech company that discovers and develops innovative medicines for high unmet medical needs, such as investigational drugs for cancer, auto-immune diseases, and chronic pain. Our AI systems rated the company B in Technicals, C in Growth, F in Low Volatility Momentum, and F in Quality Value. The stock closed up 5.03% to $20.69 on volume of 2,976,804 vs its 10-day price average of $18.09 and its 22-day price average of $18.08, and is up 17.16% for the year. Revenue grew by 42.49% in the last fiscal year, Operating Income grew by -13.91% in the last fiscal year, and EPS grew by -1.8% in the last fiscal year. Revenue was $114.62M in the last fiscal year compared to $307.71M three years ago, Operating Income was $(440.04)M in the last fiscal year compared to $(43.66)M three years ago, EPS was $(2.52) in the last fiscal year compared to $(0.62) three years ago, and ROE was (28.22%) in the last year compared to (109.91%) three years ago. ... "